Autolus Therapeutics receives Prix Galien UK award

Autolus Therapeutics, a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the Galien Foundation has presented the Company with the 2026 Prix Galien UK Award for Best Biotechnology Product. Winners of the prestigious Prix Galien awards are selected by a UK Awards Committee, which comprises 12 experts in the field who are leaders in UK healthcare.

Dr. Martin Pule, Founder and Chief Scientific Officer of Autolus, Clinical Senior Lecturer in the Department of Haematology at the UCL Cancer Institute, and Honorary Consultant in Haematology at University College London Hospital, said:  

We are honored to receive this recognition from Prix Galien UK. Autolus was founded, in collaboration with University College London, to translate pioneering scientific research into new treatment options for patients in need. As a clinician, it is tremendously rewarding to see this vision become a reality. This award reflects the dedication of our teams, whose work is driven every day by a shared commitment to patients.